Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 6/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.51 |
| ▸ | PRNP | P04156 | 1/20 | 0.51 |
| ▸ | ALOX5 | P09917 | 5/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | GAA | P10253 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.49 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL253511 | 0.91 | GAA (0.53) | MEN1KMT2APRNPALOX5MAPT | |
| SCHEMBL9948040 | 0.81 | ANO1 (0.42) | MEN1KMT2APRNPMAPTALDH1A1 | |
| SCHEMBL24470880 | 0.80 | TSHR (0.64) | MEN1KMT2AMAPTGAAALDH1A1 | |
| SCHEMBL29630224 | 0.80 | TSHR (0.64) | MEN1KMT2AMAPTGAAALDH1A1 | |
| SCHEMBL14711743 | 0.80 | ALOX5 (0.52) | MEN1KMT2APRNPALOX5MAPT | |
| SCHEMBL243503 | 0.80 | KCNH2 (0.50) | — | |
| SCHEMBL14710741 | 0.79 | MAPT (0.64) | MEN1KMT2APRNPALOX5MAPT | |
| SCHEMBL3541034 | 0.79 | MEN1 (0.65) | MEN1KMT2APRNPALOX5MAPT | |
| SCHEMBL245269 | 0.78 | ALOX5 (0.79) | MEN1KMT2APRNPALOX5MAPT | |
| SCHEMBL14709428 | 0.77 | MEN1 (0.56) | MEN1KMT2APRNPALOX5MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2588464-B1 | BENZOFURAN DERIVATIVES FOR THE TREATMENT OF HEPATITS C | BRISTOL MYERS SQUIBB CO (US) | 2014-08-06 | — | — | EP | disclosed |
| US-8445497-B2 | Compounds for the treatment of hepatitis C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-05-21 | — | — | US | disclosed |
| US-20120165344-A1 | Compounds for the Treatment of Hepatitis C | BRISTOL-MYERS SQUIBB COMPANY | 2012-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165344-A1 | Compounds for the Treatment of Hepatitis C | HAVCR2, HCCS, SLC10A1 | MEN1 4676/4885KMT2A 4624/4885PRNP 2520/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.